Holen Sie sich die Stockscreener-App
4.705
11.66%
-0.625
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Trend Tracker for (COGT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.43 Consensus PT from Brokerages - Defense World
When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com
21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World
Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance
Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire
Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - TradingView
Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Yahoo Finance UK
Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR
Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter
Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World
Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times
Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks
New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
When the Price of (COGT) Talks, People Listen - Stock Traders Daily
Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks
Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for COGT - The AM Reporter
Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq
Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating - TipRanks
Cogent Biosciences (COGT) Surprises Wall Street with Narrower-Than-Expected Q4 Loss - HPBL
Cogent Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cogent Biosciences (COGT) Reports Q4 2024 Net Loss of $67.9 Mill - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Cogent's Triple Catalyst Year Transform Rare Disease Treatment? 3 Key Trial Results Coming in 2025 - StockTitan
Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World
Long Term Trading Analysis for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat
Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat
You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World
Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FY2025 Earnings Estimate for COGT Issued By Leerink Partnrs - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.33 Consensus PT from Brokerages - Defense World
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):